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Antigen Specificity in Subsets of Mucous Membrane
Pemphigoid
Khwaja A. Rashid1,2, Hakan M. Gu¨rcan1,2 and A. Razzaque Ahmed1,2
Mucous membrane pemphigoid (MMP) has several subsets based on target antigens recognized by their sera.
MMP and ocular cicatricial pemphigoid (OCP) sera recognize b 4 integrin subunit, oral pemphigoid sera
recognize a 6 integrin subunit, and anti-epiligrin cicatricial pemphigoid sera recognize laminin 5. Our aim is to
determine if autoantibodies in the sera of patients with MMP, OCP, and oral pemphigoid (OP) recognize only
their target antigens, and to see if this specificity is maintained throughout the clinical course. An immunoblot
assay using bovine gingival lysate was used as substrate. Fifteen MMP patients, eight with OCP, and 15 OP
patients were studied before therapy and at multiple intervals during the clinical course. Absorption and
blocking studies were performed to determine binding specificity. Sera of patients with MMP and OCP
recognize only b4 integrin subunit, and sera of OP patients recognize a6 integrin throughout the clinical course.
The sera of patients in the subsets of MMP described in this report show adherence and selectivity to target
antigen during the entire clinical course, without crossover, interaction, or change. Hence, these subsets of
MMP provide an excellent model to study clinical correlation with antigen and antibody specificity, in
autoimmunity.
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INTRODUCTION
Mucous membrane pemphigoid (MMP) is a rare and chronic
autoimmune blistering disease that involves multiple mucous
membranes and the skin (Fleming and Korman, 2000). MMP
heals with scarring, resulting in significant sequelae. Blind-
ness occurs in approximately 25% of the patients, despite
aggressive immunosuppressive therapy (Fleming and
Korman, 2000). Involvement of the larynx can cause sudden
asphyxiation and death (Fleming and Korman, 2000).
Scarring in the vaginal, anal, and penile areas compromises
the quality of life, and daily living (Fleming and Korman,
2000).
MMP is characterized by the presence of antibodies to
proteins in the basement membrane zone of epithelial tissues.
A subset with antibodies to laminin 5 is referred to as anti-
epiligrin cicatricial pemphigoid (AECP) (Domloge-Hultsch
et al., 1992). Some patients may have disease limited to the
conjunctiva or may have disease that predominantly affects
the conjunctiva, in addition to involvement of other
mucosae. They are referred to as having ocular cicatricial
pemphigoid (OCP) (Foster, 1986). Patients with OCP and
generalized MMP have been found to have antibodies to a
portion of the intracytoplasmic component of human b4
integrin (Chan et al., 1999). It has been demonstrated that the
titer of these antibodies to b4 integrin correlate with disease
activity and decrease as the disease improves, and becomes
negative, when the patients go into remission (Letko et al.,
2000). In another subset of MMP, the disease is limited to the
oral cavity only. Long-term follow-up reveals that other
mucosae or the skin are not involved. Such patients are
referred to as having oral pemphigoid (OP) (Mobini et al.,
1998). Patients with OP produce an antibody to human a6
integrin subunit (Bhol et al., 2001). Long-term follow-up
studies indicate that the extent and severity of the oral disease
correlates with the titer of antibody and as patients improve
and go into a clinical remission, the antibody decreases and
eventually disappears (Sami et al., 2002).
Some authors have reported that sera of MMP patients
have antibodies to bullous pemphigoid (BP) antigens.
However, on long-term follow-up, it was observed that
antibodies to bullous pemphigoid antigen 1 (BPAg1) and
bullous pemphigoid antigen 2 (BPAg2) do not correlate
with disease activity or severity and their presence is erratic
and unpredictable (Yeh et al., 2004). This would suggest
that, although occasionally present, they are probably not
pathogenic and could be produced in response to damage
to basal epithelial cells. Hence, we did not include them in
this study.
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The purpose of this study was to determine if patients with
generalized MMP or OCP have antibodies to b4 integrin
subunit only or to a6 integrin subunit also. In addition, the
purpose of the study was to determine if the patients with OP
have antibodies only to human integrin a6 or antibodies to
human integrin b4 subunit also.
RESULTS
Immunoblot analysis of MMP and OP Sera
Sera from all 15 patients with MMP and OCP showed binding
with a 205 kDa protein (Figure 1). The binding of the sera was
identical to that of UMA9 antibody. Thus, MMP and OCP
sera identified b4 integrin subunit as the target molecule.
Binding of MMP and OCP sera to any other protein was not
observed. Binding to a6 integrin was not detected in any of
the 15 MMP sera.
Sera of 15 patients with OP demonstrated binding to a
120 kDa protein (Figure 2). This binding was identical to
binding by GoH3 antibody. Hence, the sera from 15 patients
with OP recognized a6 integrin subunit. Binding to any other
protein was not observed. Binding to b4 integrin subunit was
not observed.
The binding pattern of sera of OP and MMP patients to
bovine gingivae lysate (BGL) absorbed with only normal
human serum (NHS) and BP sera were identical. MMP, OP,
and all sera did not bind to laminin, whereas GB3 did.
Bullous pemphigoid
Sera from all 15 patients, including BP patients, when reacted
with BGL which had been absorbed with only NHS,
demonstrated binding to a 230 kDa protein (BPAg1). Binding
to a 180 kDa protein (BPAg2) was observed in 12 of the 15 BP
sera (80%) (Figure 3).
Controls
Sera from patients with pemphigus vulgaris bound to a
130 kDa (desmoglein 3) protein and a 160 kDa (desmoglein
1) protein, with pemphigus foliaceus bound to 160 kDa
protein (desmoglein 1), and with AECP bound to a 165, 150,
and 140 kDa protein (three subunits of laminin 5). The 15
NHS did not show any binding to any proteins.
Indirect immunofluorescence studies
The results of the indirect immunofluorescence, using salt-
split normal human skin as substrate, are presented in Table 1.
In all patients, the antibodies bound to the epidermal side of
salt-split skin, tested at a titer of 1:10. Binding to the dermal
side was not observed. The frequency of the Ig class was
different in the three groups. OCP had a higher frequency of
IgA antibodies. Non-ocular MMP and OP had predominantly
IgG antibodies. Control BP sera bound to epidermal side and
sera of an epidermolysis bullosa acquisita patient bound to
the dermal side of split. NHS did not show any binding.
Antigen-binding specificity of subsets
When the lysates were absorbed with NHS and BP sera, it
first reacted with (i) anti-b4 antibody (UMA9) and (ii) MMP.
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Figure 1. IB analysis of binding of MMP and OCP sera using BGL as
substrate. Lanes 1–10 show the binding of sera of five MMP and five OCP
patients to BGL absorbed with NHS and BP sera. Note the presence of binding
to 205 kDa protein. Lane 11 demonstrates binding of UMA9 mAb to 250 kDa
protein in BGL. Disease control includes binding of PV sera to desmoglein 3
observed as 130 kDa protein, and lanes 13–15 are three NHS, showing no
binding.
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Figure 2. IB assay using BGL as substrate, demonstrating the binding of
sera from patients with OP. Lanes 1–10 show the binding of 10 sera from
patients with active OP. Note binding to 120 kDa protein. Lane 11
demonstrates the binding of mAb GoH3 to BGL absorbed with NHS and BP
sera. Note binding to 120 kDa protein as a6 integrin subunit. Disease control
includes binding of PV sera to desmoglein 3 observed as 130 kDa protein.
Lanes 13–15 are three NHS, showing no binding.
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Figure 3. IB assay using BGL as substrate demonstrates binding of the sera
from patients with BP. Lanes 1–10 show the binding of sera of untreated BP
patients to BGL absorbed with NHS. Note the binding to BPAg1 (230 kDa)
protein and BPAg2 (180 kDA) protein. In lane 11, PV serum bound to
desmoglein 3 and in lane 12 PF serum bound to 160 kDa protein. Lanes 13–15
are three NHS reacted with BGL, showing no binding.
Table 1. Indirect immunofluorescence assay using 1 M
NaCl normal human split skin as substrate
Subset N IgG IgM IgA
Non-ocular MMP 7 7 1 2
Ocular MMP 8 6 2 8
OP 15 15 0 1
BP 15 15 4 2
NHS 15 0 0 0
BP, bullous pemphigoid; MMP, mucous membrane pemphigoid; NHS,
normal human serum; OP, oral pemphigoid; SSS, salt split skin.
All test sera used at 1:20 dilution for SSS assay.
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Then, it reacted with OP sera and GoH3 mAbs. Binding to a
120 kDa protein, identified as a6 integrin, was observed
(Figure 4).
When the lysates absorbed with NHS and BP, sera were
reacted first with (i) mAb to human a6 integrin (GoH3) and (ii)
OP sera. Then, they were reacted with MMP and OCP sera,
and UMA9. Binding to a 205 kDa protein, identified as b4
integrin, was observed (Figure 4).
Blocking and cross-absorption studies
When the BGL was first absorbed with MMP/OCP sera and
then reacted with UMA9 antibodies, MMP/OCP, OP sera,
and GoH3 antibodies, the following was observed. A
205 kDa protein was not identified, indicating that the b4
protein had bound to MMP/OCP sera, and b4 integrin subunit
was blocked and therefore not available to UMA9 antibodies.
In the reverse experiment, the BGL strips were first absorbed
with UMA9 antibodies. And then reacted with MMP and
OCP sera. A 205 kDa protein binding was not observed.
These experiments demonstrate that MMP/OCP sera both
bind to b4 integrin subunit and block reactivity by cross-
absorption. However, the strips reacted with GoH3 and OP
antibodies, and this was demonstrated by binding to a
120 kDa protein. This indicates that while b4 integrin was
blocked, a6 integrin is still available for binding to OP sera
and GoH3 antibodies.
When the BGL is first absorbed with OP sera and then
reacted to GoH3 antibodies, no binding to a 120 kDa band is
observed, thus indicating that OP sera bound to the 120 kDa
protein, which is a6 integrin. In the reverse experiment, when
the BGL was first absorbed with GoH3 antibodies, and then
reacted with OP sera, no binding to a 120 kDa protein was
seen. These experiments demonstrated that OP sera and
GoH3 can bind to a6 integrin and block reactivity by cross-
absorption in the same substrate. However, in both experi-
ments, binding to a 205 kDa protein was seen on strips
reacted with MMP/OCP sera and UMA9 antibody. This
indicates that b4 integrin is unaffected by these cross-
absorption studies and is available for binding to MMP/
OCP sera and UMA9 antibody. Positive controls demons-
trated BP sera binding to 180 kDa protein (BPAg2) and
230 kDa protein (BPAg1). No binding was seen with NHS.
Longitudinal immunoblot analysis of sera from subsets of MMP
The immunoblot (IB) analysis of sera from MMP and OCP
patients evaluated at 4-month intervals for 4 years demons-
trated that their sera contained antibodies to only b4 integrin
subunit. Antibodies to a6 integrin were never detected. A
representative IB analysis of one MMP and one OCP patient
is presented in Figure 5. The IB analysis of sera from OP
patients evaluated at 4 months interval, for a 4-year period
demonstrated binding to a6 integrin only. Binding to b4
integrin subunit was not observed. A representative patients’
sera analysis is present in Figure 5. Once the binding was no
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Figure 4. Blocking experiments using BGL to demonstrate the binding
specificity of sera from patients with OP and mucous membrane or OCP.
In left panel A, lane 1 demonstrates the binding of MMP sera and in lane 2
binding of UMA9 mAb to BGL absorbed with NHS and BP sera. Note 205 kDa
protein identified as human b4 integrin subunit. In lanes 3 and 4, the BGL is
first absorbed with MMP sera and UMA9 mAb, then reacted with OP sera in
lane 3 and mAb GoH3 in lane 4. Note 120 kDa protein, identified as a6
integrin. In right panel B, in lane 5, BGL absorbed NHS and BP sera reacted
with OP sera and in lane 6 reacted with mAb GoH3. Note binding to a
120 kDa protein. In lanes 7 and 8, BGL absorbed with OP sera and GoH3
reacted with MMP sera in lane 7, and UMA9 mAb in lane 8. Note binding to a
205 kDa protein, identified as human b4 integrin subunit.
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Figure 5. Longitudinal IB analysis of sera from subsets of MMP. (a) Sera from
a representative patient with MMP was followed for 36 months. The IB
analysis of sera from the patient was evaluated at 4-month intervals. Binding
to a 205 kDa protein (b4 integrin) was observed. The titer of the antibody at
each time interval has been provided. The titer of the antibody in the sera
decreases with time, becoming undetectable at the 28th month after the
initiation of therapy. UMA9 antibody and NHS were used as controls. (b) Sera
from a representative patient with OCP was followed for 36 months. The IB
analysis of sera from the patient was evaluated at 4-month intervals. Binding
to a 205 kDa protein (b4 integrin) was observed. The titer of the antibody at
each time interval has been provided. The titer of the antibody in the sera
decreases with time, becoming undetectable at the 32nd month after the
initiation of therapy. UMA9 antibody and NHS were used as controls. (c) Sera
from a representative patient with OP was followed for 36 months. The IB
analysis of sera from the patient was evaluated at 4-month intervals. Binding
to a 120 kDa protein (a6 integrin) was observed. The titer of the antibody at
each time interval has been provided. The titer of the antibody in the sera
decreases with time becoming undetectable at the 28th month after the
initiation of therapy. GoH3 antibody and NHS were used as controls.
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longer detected, the patient was considered to be in a
serological remission. Hence, data on time intervals beyond
the induction of such a remission, although performed, are
not presented in the figures. The titer of the antibody in the
sera decreases with time, because of systemic therapy and
eventually disappears.
DISCUSSION
Using an IB assay, we demonstrate that sera obtained from 15
untreated patients with mucous membrane or ocular pem-
phigoid bound only to b4 integrin subunit. They do not
contain antibodies to the a6 integrin or to laminin. Sera of
untreated patients with OP had antibodies that recognized
only a6 integrin and did not bind to the human b4 integrin
subunit or laminin. The specificity of this binding was further
confirmed in the blocking and cross-absorption studies. The
observations in the study clearly indicate that the two
components a6 and b4 of integrin heterodimer, while in
close proximity, act as autoantigens independently. Long-
term follow-up of minimum of 4 years also demonstrates that
during the clinical course patients with MMP and OCP
produce autoantibodies to only human b4 integrin subunit,
whereas patients with OP produce autoantibodies to only
human a6 integrin subunit. Switching or crossover in
autoantibody profile was not observed in the patients in this
report. The importance of these observations lie in the fact
that the clinical subsets of patients with MMP can be
classified on the basis of their antibody profiles determined
by their specific binding to the target antigens.
The features on indirect immunofluorescence studies
using salt-split normal human skin are identical to those
observed by other investigators (Bagan et al., 2005). The
presence of antibodies to BPAg1 and BPAg2 in the sera of
patients with MMP have been demonstrated to be transitory,
does not correlate to disease activity or severity, and may be a
secondary phenomenon, with no defined or specific role in
the pathogenesis of the disease process (Yeh et al., 2004). The
subset of patients referred to as having AECP produce
antibodies to laminin 5, have clinical profile completely
indistinguishable from patients with MMP, with antibodies to
b4. Based on the available data, it appears that the sera of
patients with antibodies to epiligrin or laminin 5 do not
recognize antibodies to human b4 or a6 integrin subunits.
This division of subsets of MMP, based on serologies, has
implications on therapy. Patients with MMP and OCP often
require systemic immunosuppressive therapy (Miserocchi
et al., 2002). Patients with OP often respond topical therapy
and intralesional corticosteroid injection (Mobini et al.,
1998). Patients with AECP have a poor prognosis and do
not respond very favorably to conventional immunosuppres-
sive therapy (Egan et al., 2003).
The benefit of identifying subsets of MMP is of importance
because it correlates with differences in prognosis. Of
patients with antibodies to laminin, those who have AECP
have a statistically high risk of developing solid tumors (Egan
et al., 2001). In sharp contrast, patients who have antibodies
to either a6 or b4 do not have a high incidence of
malignancy. On the contrary, they are observed to have a
lower than normal or expected frequency of incidence of
cancer (Letko et al., 2004). As laminin may be present in the
periphery of the tumor, antibodies to it could play a role in
the breakdown of the capsule or other barriers surrounding
the tumor and may facilitate tumor growth as well as
metastasis. The epitope to which the antibodies in AECP
bind are present in the a, b, and g domains of laminin 5
(Lazarova et al., 2001). The epitope in the human b4 integrin
subunit to which MMP and OCP antibodies bind is present in
the cytoplasm of the basal epithelial cells (Kumari et al.,
2001). The epitope to which the antibodies bind in patients
with OP is in the extracellular domain of a6 integrin subunit
(Rashid et al., 2006). The role of the autoantibodies to the b4
and a6 integrin subunits, if any, in preventing or protecting
from malignancy, has not been described or studied. It is
possible that as the three target antigens have different
locations, the binding of the antibody to the antigen could
generate different signals, which could affect or influence
different cellular and extracellular pathways.
Patients with MMP, OCP, and OP who are non-responsive
to systemic corticosteroids and immunosuppressive agents
have been treated with intravenous Ig (Ahmed and Dhal,
2003). A defined protocol has been used. The patients that
have demonstrated good clinical response have gone into
remission and remained in remission when followed over a
prolonged period of time. This indicates that the autoanti-
bodies to a6 and b4 can be influenced by intravenous Ig
therapy and their production can be possibly eliminated
(Letko et al., 2000; Sami et al., 2002). It is possible that the
intravenous Ig could influence the regulation of autoantibody
production through the idiotypic–anti-idiotypic network
(Lacroix-Desmazes et al., 2002).
This study highlights the importance of identifying the
clinical subsets of MMP. Once the diagnosis of MMP is made,
the antigen specificity of the antibody should be studied. The
antibody profile of the patient could have a significant
influence on the prognosis and clinical outcome. This unique
experiment in nature provides us a spectrum of clinical
profiles that correlates with autoantibody profiles, without
overlaps or crossovers. The association with malignancies
provides an opportunity to study the influence and effect of
autoantibodies to adhesion molecules on malignancy. This
will enhance our knowledge and understanding of the
pathogenesis of these diseases, the biology of the epithelium,
its reaction to the underlying submucosal, and the role of the
basement membrane in both adherence and communications.
MATERIALS AND METHODS
Patients
Fifteen patients with MMP, with involvement of at least two mucosal
surfaces, with or without the skin, were included in the study. In the
non-ocular MMP patients, the clinical profile consisted of erosive
lesions in the oral cavity, noticeably desquamative gingivitis.
Scarring in the nasal, laryngeal, and esophageal mucosa was
observed. Eight patients had predominantly ocular involvement in
addition to involvement of other mucosae. The patients were most
concerned about the ocular involvement, because of conjunctival
scarring. These patients are referred to as OCP. Whereas the clinical
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diagnosis of MMP was based on clinical presentation, it was
established by a subepithelial vesicle with a mixed infiltrate on
routine histology in all patients. The diagnosis was confirmed by the
deposition of IgG and/or complement at the basement membrane
zone on direct immunofluorescence of at least one mucosal
perilesional biopsy. All of the patients were tested for antibody
binding on salt-split skin, as a substrate. All 15 sera bound to the
epidermal side of the salt-split skin. All patients with OCP had IgA
antibodies, whereas only two of the non-ocular MMP and one of the
OP patients had IgA antibodies.
Fifteen patients with OP studied. The disease was limited to the
oral cavity only. During a long-term follow-up, involvement of other
mucosal sites was not observed. The gingiva, palate, and buccal
mucosa were the most frequently involved sites. The histology,
immunopathology, and serological features of OP were similar to
MMP patients.
The patients with MMP, OCP, and OP were clinically followed
for a minimum of 4 years. All the sera on the patients were obtained
before systemic treatment was initiated. Subsequently, the sera were
tested at every 4-month intervals, using IB assay. None of the
patients had developed a malignancy during this follow-up period or
had a malignancy before developing pemphigoid. The MMP, OCP,
and OP patients reported in this study have not been reported in any
earlier study.
Fifteen sera from patients with BP were also studied. The
diagnosis in these patients was based on the presence of large tense
bullae in an acral distribution. The histology, immunopathology, and
serological features of BP were similar to MMP patients. None of the
patients with BP had any mucosal involvement. The controls
included sera of two patients with pemphigus vulgaris, two patients
with pemphigus foliaceus, one patient with AECP, and 15 normal
healthy human volunteers. Positive controls included UMA9 mAb to
b4 integrin subunit (Ancell Corp., Bayport, MN), and GoH3 mAb to
integrin a6 (R&D systems, Minneapolis, MN). The study was
conducted according to the Declaration of Helsinki Principles. It
was approved by the Institution Review Board. The patients provided
their informed consent to participate in the study.
Indirect immunofluorescence studies
As monkey esophagus usually is not an ideal substrate to test MMP/
OCP sera, the sera were tested on normal human salt-split skin. The
sera were tested at a dilution of 1:10.
IB analysis
BGL was used as substrate. Recently, we have demonstrated that
the information obtained by using BGL is similar to that obtained
by using normal human epidermis or whole skin, as lysate in IB
analysis, when identifying antigens in autoimmune mucocutaneous
blistering diseases (Engineer et al., 2000). Bovine jaws were obtained
from a local slaughterhouse. The entire mucosa was scraped off the
jaw. The tissue so obtained was treated with tissue homogenizer.
Then the lysate was prepared by a protocol similar to that for human
skin or bovine tongue. The details have been described previously
(Bhol et al., 2001).
A unique feature of this IB assay included absorption with the
test lysate with NHS and sera from patients with BP. This additional
step was as follows. Protein A sepharose beads were washed
and equilibrated in 50 mM phosphate buffer (pH 8.0). After
equilibration, the beads were suspended in NHS and mixed
overnight at 41C by rotation. The unbound serum proteins were
washed by 50 mM phosphate buffer (pH 8.0), 100 mM NaCl, and
0.05% Tween. The beads were then packed into a column. Total
protein concentration of the BGL sample loaded onto the column
was 10 mg. This BGL preparation was passed through the column
with the protein A sepharose beads coated with NHS. Thus, proteins
present in BGL that were recognized by NHS were absorbed and
eliminated.
The process was repeated twice to ensure removal of as many
proteins from BGL that could be recognized by NHS. Half of this
lysate was used as such for IB analysis in studies in this report. Half
of the remaining lysate was depleted of antigens associated with BP
by the following technique.
Protein A sepharose columns bound with serum from patients
with BP were prepared as described above. The BGL proteins eluted
from protein A sepharose column bound to NHS were then passed
through this protein A sepharose column, which was immobilized
with serum from BP patient, as described above. Using indirect
immunofluorescence assay, it was determined that these sera had
high titers of anti-basement membrane zone antibodies. By IB, it was
confirmed that the anti-basement membrane zone antibodies were
against both BPAg1 and BPAg2. This additional step facilitated the
removal of BP antigens from the BGL to be used in the IB analysis.
Thus, two batches of the BGL were finally prepared for the study.
One in which the BP antigens were present, and the other in which
the BP antigens had been removed.
The BGL was run on SDS-PAGE, and the proteins transferred to
a nitrocellulose membrane as described earlier (Bhol et al., 2001).
Sera from the 15 patients with MMP and 15 patients with OP
were reacted with BGL, absorbed with both normal human sera and
sera of BP patients. The sera from 15 patients with BP, 15 normal,
and four pemphigus patients were reacted with BGL, which had
been absorbed only with the normal human sera.
Antigen-binding specificity of subsets
BGL was first absorbed with MMP and OCP sera. The control BGL
strip was reacted with MMP and OCP sera, and UMA9 mAb only.
Then, the same nitrocellulose strips were reacted with sera from OP
patients and GoH3 antibodies.
BGL was first absorbed with OP sera and then GoH3 antibodies.
The same nitrocellulose strips were reacted with sera from MMP,
OCP patients and antibodies to b4 integrin (UMA9). Control strip of
BGL was reacted with BP sera or GoH3 mAb only.
Blocking and cross-absorption studies
In the reverse experiment, the BGL strips were first reacted with
UMA9 (mAb to b4 integrin) and then reacted with MMP and OCP
sera, which were known to have high titers of antibodies to b4
integrin. The control BGL strip was reacted with UMA9 antibodies,
MMP/OCP sera, OP sera, and GoH3 antibodies.
In the reverse experiment, the BGL was first absorbed
with GoH3. These strips were then absorbed with OP sera (with
known high titers to a6 integrin), MMP/OCP sera, and UMA9
antibodies.
Positive controls in both sets of experiments were two sera from
patients with acute untreated BP, which were reacted with BGL not
absorbed with BP sera. Negative control was NHS.
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Longitudinal IB analysis of sera from subsets of MMP
Using the above-described IB assay, sera collected at 4-month
intervals were evaluated for the presence of antibodies to b4 integrin
subunit and a6 integrin. In the 30 patients in this study, UMA9 and
GoH3 antibodies were used as controls.
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